Loading...
ALC logo

Alcon Inc.NYSE:ALC Stock Report

Market Cap US$32.0b
Share Price
n/a
1Y-14.7%
7D-6.3%
1D-0.8%
Portfolio Value
​
View

Alcon Inc.

NYSE:ALC Stock Report

Market Cap: US$32.0b

Alcon (ALC) Stock Overview

Researches, develops, manufactures, distributes, and sells eye care products worldwide. More details

ALC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance1/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 45.7% below our estimate of its fair value

Earnings are forecast to grow 25.74% per year

Analysts in good agreement that stock price will rise by 38.2%

Risk Analysis

Large one-off items impacting financial results

Profit margins (5.9%) are lower than last year (10.7%)


ALC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW443,000 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
443,000 investors already sharing narratives
View all narratives

Alcon Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alcon
Historical stock prices
Current Share PriceCHF 66.03
52 Week HighCHF 87.64
52 Week LowCHF 61.84
Beta0.70
1 Month Change-11.07%
3 Month Change0.29%
1 Year Change-14.70%
3 Year Change-18.66%
5 Year Change-21.59%
Change since IPO13.77%

Recent News & Updates

Seeking Alpha • Aug 14

Alcon: Historical Growth Significantly Understates Potential

Summary Alcon's installed base anchors a highly attractive stream of high-margin recurring consumables revenue - a classic "razor / razor-blade" model. We believe Alcon's current 20% operating profit margin remains well below its structural potential. We believe that revenue growth combined with significant margin expansion should see Alcon grow its earnings at a mid-teens rate. We anticipate Alcon can generate meaningful compounded returns from current levels. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Aug 14

Alcon: Historical Growth Significantly Understates Potential

Summary Alcon's installed base anchors a highly attractive stream of high-margin recurring consumables revenue - a classic "razor / razor-blade" model. We believe Alcon's current 20% operating profit margin remains well below its structural potential. We believe that revenue growth combined with significant margin expansion should see Alcon grow its earnings at a mid-teens rate. We anticipate Alcon can generate meaningful compounded returns from current levels. Read the full article on Seeking Alpha
Seeking Alpha • Feb 04

Alcon: An Eyecare Leader With Strong Profit Margins, But Overheated Valuation

Summary Alcon is downgraded to a hold from my buy rating in fall 2023, after it has gone up +18% since then and now appears overvalued with a 48x earnings multiple. The firm has a strong profit margin vs its sector, low debt/equity vs a key peer Bausch & Lomb, and investment-grade credit ratings. Its positive cashflow growth should help sustain its dividend. Some risks in this sector are product recalls and supply-chain disruptions, as past events have shown us. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Alcon Q2: Positive News From Unity VCS/CS And AR-15512

Summary I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set for U.S. commercialization in 2025, enhancing their competitive edge in cataract and vitreoretinal surgery markets. Alcon's partnership with Ocumension in China will leverage local distribution and manufacturing to expand their dry eye treatment business, including Systane Ultra and AR-15512. Despite some U.S. market challenges, I project Alcon to achieve 7% organic revenue growth, supported by product innovation and strategic acquisitions. Read the full article on Seeking Alpha
Seeking Alpha • Aug 01

Alcon: Trading At An Undeserved Premium Valuation

Summary Global eye care giant Alcon, Inc. has seen its stock rise some 30% since its late October lows. The company is delivering solid, but hardly spectacular revenue growth, and is seeing much better free cash flow. The stock now trades at a significant valuation premium to the overall market. Is that premium valuation deserved? An analysis of Alcon follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 14

Alcon Q1: Robust Product Pipeline Drives Future Growth (Rating Upgrade)

Summary Alcon has experienced robust Q1 growth, driven by double-digit growth in vision care, particularly in the contact lens market. The company's strong revenue growth is attributed to successful product launches, such as TOTAL30 and DAILIES TOTAL1, which have helped Alcon gain market share. Alcon's FY24 forecast shows potential for increased free cash flow, strong revenue growth in vision care, and growth opportunities in the surgical business. Read the full article on Seeking Alpha
Seeking Alpha • Oct 10

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Summary Alcon gets a Buy Rating today, in line with Wall Street consensus. Strengths include earnings growth, share price crossover below 200-day average, outperformance vs. the S&P500 index, and the company's strong cash position. Offsetting factors include a high valuation and poor dividend yield. The downside risk of debt levels was also addressed. Read the full article on Seeking Alpha
Seeking Alpha • Jul 26

Alcon: Lackluster Growth Given Its Valuation

Summary Alcon stock is currently trading at over 30x earnings, which is considered high for a company not expected to deliver EPS above 20 - 25% in the next few years. Despite the high trading multiple, Alcon has a strong business model and is a leader in the eye care industry, with recent positive developments in its product line and services. Alcon's share price is currently inflated due to hopes of significant free cash flow being diverted to shareholders, but I suggest this optimism may be misplaced and recommend a hold rating for the company. Read the full article on Seeking Alpha
Seeking Alpha • Jun 27

Alcon: The Steady Force Of 'Boring'

Summary Alcon is expected to outpace market growth and gain market share in the surgical and vision care sectors, with growth driven by factors such as the increasing global aging population and rise in myopia. Along with Costco, Aon, and Marsh & McLennan, Alcon is another "boring" investment in my portfolio. Alcon's focus on R&D, product innovation, and accelerated free cash flow generation contribute to a positive outlook, earning a "Buy" rating. Read the full article on Seeking Alpha

Shareholder Returns

ALCUS Medical EquipmentUS Market
7D-6.3%-5.5%-0.9%
1Y-14.7%-18.1%13.9%

Return vs Industry: ALC exceeded the US Medical Equipment industry which returned -19% over the past year.

Return vs Market: ALC underperformed the US Market which returned 14.2% over the past year.

Price Volatility

Is ALC's price volatile compared to industry and market?
ALC volatility
ALC Average Weekly Movement3.7%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: ALC has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ALC's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
194525,000David Endicottwww.alcon.com

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures.

Alcon Inc. Fundamentals Summary

How do Alcon's earnings and revenue compare to its market cap?
ALC fundamental statistics
Market capUS$31.95b
Earnings (TTM)US$643.00m
Revenue (TTM)US$10.86b
49.7x
P/E Ratio
2.9x
P/S Ratio

Is ALC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALC income statement (TTM)
RevenueUS$10.86b
Cost of RevenueUS$4.65b
Gross ProfitUS$6.22b
Other ExpensesUS$5.57b
EarningsUS$643.00m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Nov 11, 2026

Earnings per share (EPS)1.33
Gross Margin57.22%
Net Profit Margin5.92%
Debt/Equity Ratio21.9%

How did ALC perform over the long term?

See historical performance and comparison

Dividends

0.5%
Current Dividend Yield
27%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 18:02
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alcon Inc. is covered by 60 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
null nullBaird
Jeffrey JohnsonBaird